HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.

AbstractPURPOSE:
Folate receptor (FR) targeted drug conjugates were prepared by covalently attaching the vitamin folate, to the potent anticancer drug, mitomycin C (MMC). One such conjugate, called EC72, was synthesized with an intramolecular disulfide bond, and it was found to exhibit efficacious anti-tumor activity against FR-expressing M109 tumors in a manner that yielded no gross or microscopic toxicity, even to FR-positive kidneys.
METHODS:
EC72's specificity was demonstrated by two methods: (1) blocking EC72's activity with an excess of co-administered folic acid (FA) in M109 tumor bearing mice and (2) the absence of therapeutic activity in mice bearing FR-negative tumors. The importance of having a cleavable bond in the conjugate was also exemplified, since EC110 (a folate-MMC conjugate constructed with a more resilient amide bond) failed to produce anti-M109 tumor activity. EC72's therapeutic potential was found to decrease with respect to the increasing size of subcutaneous tumor. However, a combination therapy with paclitaxel reproducibly improved the anti-tumor efficacy relative to either agent alone at well tolerated dose levels and with no apparent increase in toxicity. A more advanced folate-MMC conjugate was also synthesized in an effort to improve activity. Thus, EC118, a molecule constructed with both a reducible disulfide bond and an acid-labile hydrazone bond in the linker region, was tested and found to produce a significantly greater number of tumor regressions of more established M109 tumors than that achieved with EC72.
CONCLUSION:
Overall, these data indicate that folate-targeted drug therapy alone, or in combination with paclitaxel, may be a novel and effective clinical approach towards treating FR-positive cancers.
AuthorsJoseph A Reddy, Elaine Westrick, Iontcho Vlahov, Stephen J Howard, Hari Krishna Santhapuram, Christopher P Leamon
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 58 Issue 2 Pg. 229-36 (Aug 2006) ISSN: 0344-5704 [Print] Germany
PMID16331500 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Carrier Proteins
  • Folate Receptors, GPI-Anchored
  • Receptors, Cell Surface
  • Mitomycin
  • Folic Acid
Topics
  • Animals
  • Antineoplastic Agents, Phytogenic (administration & dosage, chemistry, pharmacology)
  • Carrier Proteins (physiology)
  • Folate Receptors, GPI-Anchored
  • Folic Acid (administration & dosage, chemistry, pharmacology)
  • Mice
  • Mitomycin (administration & dosage, chemistry, pharmacology)
  • Receptors, Cell Surface (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: